Related Experiment Videos
[Combined therapy with polyamine biosynthesis inhibitors and mitomycin C]
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|June 1, 1984
Summary
Combined therapy with alpha-difluoromethylornithine (DFMO), methylglyoxal-bis-guanylhydrazone (MGBG), and mitomycin C (MMC) effectively suppressed gastric cancer growth. However, tumor regrowth and DNA biosynthesis accelerated after DFMO/MGBG cessation, unlike MMC treatment.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Context:
- Human gastric cancer xenografts in BALB/c nu/nu mice were used to study tumor response.
- Therapeutic efficacy was assessed after cessation of combined treatments.
Purpose:
- To analyze tumor growth dynamics and DNA biosynthesis following the discontinuation of combined polyamine biosynthesis inhibitors (DFMO, MGBG) and mitomycin C (MMC).
Summary:
- The combination of DFMO and MGBG initially stunted tumor growth but led to accelerated growth and DNA biosynthesis post-treatment.
- Mitomycin C (MMC) halted tumor growth, with near-complete recovery of growth rate and DNA biosynthesis observed 5 days after its cessation.
- The triple combination (DFMO, MGBG, MMC) suppressed tumor growth and DNA biosynthesis for over 7 days, with extensive histological damage observed post-treatment.
Impact:
- This study highlights the differential impact of combined therapies on tumor regrowth and DNA replication.
- Findings suggest that the combination including MMC offers more sustained tumor suppression compared to polyamine biosynthesis inhibitors alone.